SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Q3 product rev €366M +89%

Ascendis Pharma, LLC · PRESS-RELEASE filed Nov 12, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Nov 12, 2026 at 07:30 ET

Ascendis Pharma reported Q3 2026 product revenue of €366M (+89% YoY), driven by YORVIPATH (€291M, +103% YoY). GAAP EPS was €1.08 per diluted share, below the consensus estimate of $1.12 per ADS. The company achieved its first operating profit (€125M, 34% margin) and raised full-year operating cash flow guidance to at least €600M.

  • Q3 2026 product revenue €366M, +89% YoY
  • YORVIPATH revenue €291M, +103% YoY
  • GAAP diluted EPS €1.08 vs consensus $1.12 (miss)
  • Non-IFRS diluted EPS €1.71

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access